본문 바로가기
KERD
논문KCI 등재

Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer

Kim Kyung-Hee|Shin Dong Hoon|Choi Minyoung|Kim Sang Soo|Jo Jeong Yeon|Bae Young-Ki
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2023.12|Experimental and Molecular Medicine|제55권 |pp. 2220-2237|DOI 10.1038/s12276-023-01091-0

2

조회

0

다운로드

0

인용

0

참고문헌

주제분류생화학

초록

Kirsten rat sarcoma viral oncogene homologue (KRAS) is a frequent oncogenic driver of solid tumors, including non-small cell lung cancer (NSCLC). The treatment and outcomes of KRAS-mutant cancers have not been dramatically revolutionized by direct KRAS-targeted therapies because of the lack of deep binding pockets for specific small molecule inhibitors. Here, we demonstrated that the mRNA and protein levels of the class III histone deacetylase SIRT1 were upregulated by the KRASMut-Raf-MEK-c-Myc axis in KRASMut lung cancer cells and in lung tumors of a mouse model with spontaneous KrasG12D expression. KRASMut-induced SIRT1 bound to KRASMut and stably deacetylated KRASMut at lysine 104, which increased KRASMut activity. SIRT1 knockdown (K/D) or the SIRT1H363Y mutation increased KRASMut acetylation, which decreased KRASMut activity and sensitized tumors to the anticancer effects of cisplatin and erlotinib. Furthermore, in KrasG12D/+;Sirt1co/co mice, treatment with cisplatin and erlotinib robustly reduced the tumor burden and increased survival rates compared with those in spontaneous LSL-KrasG12D/+;Sirt1+/+ mice and mice in each single-drug treatment group. Then, we identified p300 as a KRASMut acetyltransferase that reinforced KRASMut lysine 104 acetylation and robustly decreased KRASMut activity. KRASMut lysine 104 acetylation by p300 and deacetylation by SIRT1 were confirmed by LC‒MS/MS. Consistent with this finding, the SIRT1 inhibitor EX527 suppressed KRASMut activity, which synergistically abolished cell proliferation and colony formation, as well as the tumor burden in KRASMut mice, when combined with cisplatin or erlotinib. Our data reveal a novel pathway critical for the regulation of KRASMut lung cancer progression and provide important evidence for the potential application of SIRT1 inhibitors and p300 activators for the combination treatment of KRASMut lung cancer patients.

Abstract

Kirsten rat sarcoma viral oncogene homologue (KRAS) is a frequent oncogenic driver of solid tumors, including non-small cell lung cancer (NSCLC). The treatment and outcomes of KRAS-mutant cancers have not been dramatically revolutionized by direct KRAS-targeted therapies because of the lack of deep binding pockets for specific small molecule inhibitors. Here, we demonstrated that the mRNA and protein levels of the class III histone deacetylase SIRT1 were upregulated by the KRASMut-Raf-MEK-c-Myc axis in KRASMut lung cancer cells and in lung tumors of a mouse model with spontaneous KrasG12D expression. KRASMut-induced SIRT1 bound to KRASMut and stably deacetylated KRASMut at lysine 104, which increased KRASMut activity. SIRT1 knockdown (K/D) or the SIRT1H363Y mutation increased KRASMut acetylation, which decreased KRASMut activity and sensitized tumors to the anticancer effects of cisplatin and erlotinib. Furthermore, in KrasG12D/+;Sirt1co/co mice, treatment with cisplatin and erlotinib robustly reduced the tumor burden and increased survival rates compared with those in spontaneous LSL-KrasG12D/+;Sirt1+/+ mice and mice in each single-drug treatment group. Then, we identified p300 as a KRASMut acetyltransferase that reinforced KRASMut lysine 104 acetylation and robustly decreased KRASMut activity. KRASMut lysine 104 acetylation by p300 and deacetylation by SIRT1 were confirmed by LC‒MS/MS. Consistent with this finding, the SIRT1 inhibitor EX527 suppressed KRASMut activity, which synergistically abolished cell proliferation and colony formation, as well as the tumor burden in KRASMut mice, when combined with cisplatin or erlotinib. Our data reveal a novel pathway critical for the regulation of KRASMut lung cancer progression and provide important evidence for the potential application of SIRT1 inhibitors and p300 activators for the combination treatment of KRASMut lung cancer patients.

참고문헌 (77)

  1. Ferlay, J., "Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012", Int. J. Cancer, 136, pp.E359~E386 (2015)
  2. Wong, M., "Incidence arend mortality of lung cancer : global trends and association with socioeconomic status", Sci. Rep, 7, pp.1~9 (2017)
  3. Brambilla, E., "The new World Health Organization classification of lung tumours", Eur. Resp. J, 18, pp.1059~1068 (2001)
  4. Group NM-aC., "Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data", Lancet, 383, pp.1561~1571 (2014)
  5. Chevallier, M., "Oncogenic driver mutations in non-small cell lung cancer : past, present and future", World J. Clin. Oncol, 12, pp.217~ (2021)
  6. Wennerberg, K., "The Ras superfamily at a glance", J. Cell Sci, 118, pp.843~846 (2005)
  7. Johnson, L., "K-ras is an essential gene in the mouse with partial functional overlap with N-ras", Genes Dev, 11, pp.2468~2481 (1997)
  8. DuPage, M., "Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase", Nat. Protoc, 4, pp.1064~1072 (2009)
  9. Malumbres, M., "RAS oncogenes : the first 30 years", Nat. Rev. Cancer, 3, pp.459~465 (2003)
  10. Ostrem, J. M., "K-Ras (G12C)inhibitors allosterically control GTP affinity and effector interactions", Nature, 503, pp.548~551 (2013)
  11. Misale, S., "KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibitionPI3K targeting overcomes resistance to KRAS G12C inhibitors", Clin. Cancer Res, 25, pp.796~807 (2019)
  12. Solanki, H. S., "Cell type–specific adaptive signaling responses to KRASG12C inhibition cell-type specific adaption to KRASG12C inhibition", Clin. Cancer Res, 27, pp.2533~2548 (2021)
  13. Luo, J., "Overcoming KRAS-mutant lung cancer", Am. Soc. Clin. Oncol. Educ. Book, 41, pp.700~710 (2022)
  14. Hancock, J. F., "All ras proteins are polyisoprenylated but only some are palmitoylated", Cell, 57, pp.1167~1177 (1989)
  15. Sasaki, A. T., "Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors", Sci. Signal, 4, pp.ra13~ra13 (2011)
  16. Yang, M. H., "Regulation of RAS oncogenicity by acetylation", Proc. Natl Acad. Sci. USA, 109, pp.10843~10848 (2012)
  17. Qiu, X., "Sirtuin regulation in calorie restriction", Biochim. Biophys. Acta(BBA)-Proteins Proteom, 1804, pp.1576~1583 (2010)
  18. Cen, Y., "Advances in characterization of human sirtuin isoforms : chemistries, targets and therapeutic applications", Curr. Med. Chem, 18, pp.1919~1935 (2011)
  19. Xu, C., "SIRT1 is downregulated by autophagy in senescence and ageing", Nat. Cell Biol, 22, pp.1170~1179 (2020)
  20. He, F., "SIRT1 inhibits apoptosis by promoting autophagic flux in human nucleus pulposus cells in the key stage of degeneration via ERK signal pathway", BioMed. Res. Int, 2021, pp.8818713~ (2021)
  21. Rada, P., "SIRT1 controls acetaminophen hepatotoxicity by modulating inflammation and oxidative stress", Antioxid. redox Signal, 28, pp.1187~1208 (2018)
  22. Liang, D., "SIRT1", PGC-1 pathway activation triggers autophagy, Biochimie, pp.2020, 170[DOI]
  23. Qiang, L., "Proatherogenic abnormalities of lipid metabolism in SirT1 transgenic mice are mediated through Creb deacetylation", Cell Metab, 14, pp.758~767 (2011)
  24. Lin, Z., "The roles of SIRT1 in cancer", Genes Cancer, 4, pp.97~104 (2013)
  25. Wang, R. -H., "Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice", Cancer Cell, 14, pp.312~323 (2008)
  26. Jang, S. -H., "Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma", J. Clin. Pathol, 65, pp.735~739 (2012)
  27. Tamm, I., "Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias", Clin. Cancer Res, 6, pp.1796~1803 (2000)
  28. 정원경, "SIRT1 Expression Is Associated with Good Prognosis in Colorectal Cancer", Journal of Pathology and Translational Medicine, 47(4), pp.332~339 (2013), 대한병리학회[DOI]
  29. Zhang, Y., "SIRT1 is reduced in gastric adenocarcinoma and acts as a potential tumor suppressor in gastric cancer", Gastrointest. Tumors, 2, pp.109~123 (2015)
  30. Kikuchi, K., "Association of SIRT1 and tumor suppressor gene TAp63 expression in head and neck squamous cell carcinoma", Tumor Biol, 36, pp.7865~7872 (2015)
  31. Herranz, D., "SIRT1 : recent lessons from mouse models", Nat. Rev. Cancer, 10, pp.819~823 (2010)
  32. Wu, M., "Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer", Med. Oncol, 29, pp.3240~3249 (2012)
  33. Huffman, D. M., "SIRT1 is significantly elevated in mouse and human prostate cancer", Cancer Res, 67, pp.6612~6618 (2007)
  34. Chen, H. -C., "SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis", Ann. Surg. Oncol, 19, pp.2011~2019 (2012)
  35. Li, L., "Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib", Cancer Cell, 21, pp.266~281 (2012)
  36. Li, C., "SIRT1 expression is associated with poor prognosis of lung adenocarcinoma", OncoTargets Ther, 8, pp.977~ (2015)
  37. Noh, S. J., "Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer", Pathol. Res. Pract, 209, pp.365~370 (2013)
  38. Herranz, D., "SIRT1 promotes thyroid carcinogenesis driven by PTEN deficiency", Oncogene, 32, pp.4052~4056 (2013)
  39. Leko, V., "Enterocyte-specific inactivation of SIRT1 reduces tumor load in the APC+", min mouse model, 2013, pp.8, e66283~
  40. Costa-Machado, L. F., "Sirt1 protects from K-Ras-driven lung carcinogenesis", EMBO Rep, 19, pp.e43879~ (2018)
  41. Sun, J. -M., "Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer", PLoS ONE, 8, pp.e64816~ (2013)
  42. Linardou, H., "Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents : a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer", Lancet Oncol, 9, pp.962~972 (2008)
  43. Cox, A. D., "Drugging the undruggable RAS : Mission possible?", Nat. Rev. Drug Discov, 13, pp.828~851 (2014)
  44. Oberdoerffer, P., "SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging", Cell, 135, pp.907~918 (2008)
  45. O’Hagan, H. M., "Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands", Cancer Cell, 20, pp.606~619 (2011)
  46. Ashton, J. C., "Drug combination studies and their synergy quantification using the Chou–Talalay method", Cancer Res, 75, pp.2400~2400 (2015)
  47. Wang, L., "ASEB : a web server for KAT-specific acetylation site prediction", Nucleic Acids Res, 40, pp.W376~W379 (2012)
  48. Cowley, M. J., "PINA v2. 0: mining interactome modules", Nucleic Acids Res, 40, pp.D862~D865 (2012)
  49. Szklarczyk, D., "STRING v10 : protein–protein interaction networks, integrated over the tree of life", Nucleic Acids Res, 43, pp.D447~D452 (2015)
  50. Grbesa, I., "Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients", PLoS ONE, 10, pp.e0124670~ (2015)
  51. Pathria, G., "Ronai ZeA.MAPK signaling regulates c‐MYC for melanoma cell adaptation to asparagine restriction", EMBO Rep, 22, pp.e51436~ (2021)
  52. Ala, M., "Target c-Myc to treat pancreatic cancer", Cancer Biol. Ther, 23, pp.34~50 (2022)
  53. Kriegl, L., "Up-regulation of c-MYC and SIRT1expression correlates with malignant transformation in the serrated route to colorectal cancer", Oncotarget, 3, pp.1182~ (2012)
  54. Liu, P., "The histone deacetylase SIRT2 stabilizes Myc oncoproteins", Cell Death Differ, 20, pp.503~514 (2013)
  55. Yang, M. H., "HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS-regulation of K-RAS acetylation", Mol. Cancer Res, 11, pp.1072~1077 (2013)
  56. Li, L., "SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells", Cell Stem Cell, 15, pp.431~446 (2014)
  57. Hori, Y. S., "Regulation of FOXOs and p53 by SIRT1modulators under oxidative stress", PLoS ONE, 8, pp.e73875~ (2013)
  58. Yeung, F., "Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase", EMBO J, 23, pp.2369~2380 (2004)
  59. Lim, J. -H., "Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1α", Mol. Cell, 38, pp.864~878 (2010)
  60. Guan, D., "Deacetylation of the tumor suppressor protein PML regulates hydrogen peroxide-induced cell death", Cell Death Dis, 5, pp.e1340~e1340 (2014)
  61. 정재민, "SIRT1 promotes DNA repair activity and deacetylation of Ku70", Experimental and Molecular Medicine, 39(1), pp.8~13 (2007), 생화학분자생물학회
  62. Lan, F., "SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1 : possible role in AMP-activated protein kinase activation", J. Biol. Chem, 283, pp.27628~27635 (2008)
  63. Pantsar, T., "The current understanding of KRAS protein structure and dynamics", Comput. Struct. Biotechnol. J, 18, pp.189~198 (2020)
  64. Yin, G., "A KRAS GTPase K104Q mutant retains downstream signaling by offsetting defects in regulation", J. Biol. Chem, 292, pp.4446~4456 (2017)
  65. Zheng, X., "ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation", Cancer Biol. Ther, 8, pp.1045~1054 (2009)
  66. Gnosa, S. P., "ADAM17-mediated EGFR ligand shedding directs macrophagepromoted cancer cell invasion", JCI insight, 7, pp.1~21 (2022)
  67. Jackson, E. L., "Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras", Genes Dev, 15, pp.3243~3248 (2001)
  68. Nguyen, K. -S. H., "Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancers dependent on the epidermal growth factor receptor pathway", Clin. Lung Cancer, 10, pp.281~289 (2009)
  69. Prior, I. A., "A comprehensive survey of Ras mutations in cancer", Cancer Res, 72, pp.2457~2467 (2012)
  70. Konstantinopoulos, P. A., "Posttranslational modifications and regulation of the RAS superfamily of GTPases as anticancer targets", Nat. Rev. Drug Discov, 6, pp.541~555 (2007)
  71. Wang, W. -H., "Post-translational modification of KRAS : potential targets for cancer therapy", Acta Pharmacol. Sin, 42, pp.1201~1211 (2021)
  72. Zeng, T., "Impeded Nedd4-1-mediated Ras degradation underlies Ras-driven tumorigenesis", Cell Rep, 7, pp.871~882 (2014)
  73. Song, H. Y., "SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status", Oncotarget, 7, pp.80336~ (2016)
  74. Levy, D. E., "What does Stat3 do?", J. Clin. Investig, 109, pp.1143~1148 (2002)
  75. Alvarez, J. V., "Signal transducer and activator of transcription 3 is required for the oncogenic effects of non–small-cell lung cancer–associated mutations of the epidermal growth factor receptor", Cancer Res, 66, pp.3162~3168 (2006)
  76. Shi, D., "CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53", Proc. Natl Acad. Sci. USA, 106, pp.16275~16280 (2009)
  77. Fermento M. E., "RETRACTED: Intracellular distribution of p300 and its differential recruitment to aggresomes in breast cancer" (2010), Elsevier

관련 논문AI추천

Targeting TGF-β–Smad2/3–JNK1-mediated SIRT1 activity overcomes the chemoresistance of KRAS mutation lung cancerChoi Minyoung, Han Chungyong, Kim Sang Soo, Shin Dong Hoon생화학분자생물학회 · Experimental and Molecular Medicine2025 · 제57권 High expression of RAD51 promotes DNA damage repair and survival in KRAS-mutant lung cancer cellsJinfang Hu, Lei Han, Lei Zhao, Li Li, Wei Zuo, Zhiguo Zhang생화학분자생물학회 · BMB Reports2019 · 제52권 제2호SIRT1 ISGylation accelerates tumor progression by unleashing SIRT1 from the inactive state to promote its deacetylase activity송현규, 장규윤, 정명자, 허강민, Choi Cheol Yong, Cho Sang Woo, Chung Chaeuk, Han Hye Gyeong, Jeon Young Joo, Kang Ji An, Kim Min-Jung, Kim Yoon Jung, Kim You-Sun, Lee Cheol-Jung, Lee Haeseung, Lee Seonjeong, Moon Hye Won, Yoo Yoon Sun생화학분자생물학회 · Experimental and Molecular Medicine2024 · 제56권 KRAS Mutation Detection in Non-small Cell Lung Cancer Using a Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Method and Comparative Validation with Next-Generation Sequencing권미정, 이보람, 이보인, 최윤라, 한강민, 한정호대한병리학회 · Journal of Pathology and Translational Medicine2014 · 제48권 제2호KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer김동완, 김범석, 김지연, 김태민, 박세훈, 서범석, 이세훈, 허대석대한내과학회 · The Korean Journal of Internal Medicine2017 · 제32권 제3호Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer신현석, 이승룡, 이진환, 최주환대한암학회 · Cancer Research and Treatment2022 · 제54권 제2호

이 간행물의 다른 논문 (225건)

Endothelial senescence in vascular diseases: current understanding and future opportunities in senotherapeutics김성영, Han Yeaeunpp. 1-12Grave-to-cradle: human embryonic lineage tracing from the postmortem bodyKu Eu Jeong, Choi Seock Hwan, Choi Yujin Angelina, Oh Ji Wonpp. 13-21Chromatin and noncoding RNA-mediated mechanisms of gastric tumorigenesisKim Tae-Hee, Loe Adrian Kwan Ho, Zhu Lexinpp. 22-31TPX2 prompts mitotic survival via the induction of BCL2L1 through YAP1 protein stabilization in human embryonic stem cellsCha Hyuk-Jin, Kim Yun-Jeong, Go Young-Hyun, 정호창, Kwon Eun-Ji, Kim Seong-Min, Cheong Hyun Sub, Kim Wantae, Shin Hyoung Doo, Lee Haeseungpp. 32-42ZBTB7A suppresses glioblastoma tumorigenesis through the transcriptional repression of EPB41L5Nam Hae Yun, 김성학, 김승후, 최경철, Park Seung-Ho, Song Ji-Hye, Jeong Ji-Hoon, Kim Hyunhee, Jeong Minseok, Kong Min-Jeong, Son Jihyun, Jeong Ji-Eunpp. 43-54
원문 보기